Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 m...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marie Jaspard, Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, Valerie Pourcher
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Centers for Disease Control and Prevention 2020-08-01
coleção:	Emerging Infectious Diseases
Assuntos:	Tuberculosis MDR-XDR linezolid neuropathy pharmacokinetics tuberculosis and other mycobacteria
Acesso em linha:	https://wwwnc.cdc.gov/eid/article/26/8/19-1499_article
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!